205 related articles for article (PubMed ID: 36815785)
21. Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines.
Schellenbacher C; Roden R; Kirnbauer R
J Virol; 2009 Oct; 83(19):10085-95. PubMed ID: 19640991
[TBL] [Abstract][Full Text] [Related]
22. Study of infectious virus production from HPV18/16 capsid chimeras.
Chen HS; Bromberg-White J; Conway MJ; Alam S; Meyers C
Virology; 2010 Sep; 405(2):289-99. PubMed ID: 20598725
[TBL] [Abstract][Full Text] [Related]
23. Developments in L2-based human papillomavirus (HPV) vaccines.
Schellenbacher C; Roden RBS; Kirnbauer R
Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
[TBL] [Abstract][Full Text] [Related]
24. Interaction of human papillomavirus (HPV) type 16 capsid proteins with HPV DNA requires an intact L2 N-terminal sequence.
Zhou J; Sun XY; Louis K; Frazer IH
J Virol; 1994 Feb; 68(2):619-25. PubMed ID: 8289365
[TBL] [Abstract][Full Text] [Related]
25. Topography of the Human Papillomavirus Minor Capsid Protein L2 during Vesicular Trafficking of Infectious Entry.
DiGiuseppe S; Keiffer TR; Bienkowska-Haba M; Luszczek W; Guion LG; Müller M; Sapp M
J Virol; 2015 Oct; 89(20):10442-52. PubMed ID: 26246568
[TBL] [Abstract][Full Text] [Related]
26. Mutations in human papillomavirus type 16 L1 hypervariable surface-exposed loops affect L2 binding and DNA encapsidation.
Faust H; Dillner J
J Gen Virol; 2013 Aug; 94(Pt 8):1841-1849. PubMed ID: 23658208
[TBL] [Abstract][Full Text] [Related]
27. In silico/In vivo analysis of high-risk papillomavirus L1 and L2 conserved sequences for development of cross-subtype prophylactic vaccine.
Namvar A; Bolhassani A; Javadi G; Noormohammadi Z
Sci Rep; 2019 Oct; 9(1):15225. PubMed ID: 31645650
[TBL] [Abstract][Full Text] [Related]
28. An L2 SUMO interacting motif is important for PML localization and infection of human papillomavirus type 16.
Bund T; Spoden GA; Koynov K; Hellmann N; Boukhallouk F; Arnold P; Hinderberger D; Florin L
Cell Microbiol; 2014 Aug; 16(8):1179-200. PubMed ID: 24444361
[TBL] [Abstract][Full Text] [Related]
29. L1 and L2 gene polymorphisms in HPV-58 and HPV-33: implications for vaccine design and diagnosis.
Chen Z; Jing Y; Wen Q; Ding X; Zhang S; Wang T; Zhang Y; Zhang J
Virol J; 2016 Oct; 13(1):167. PubMed ID: 27717385
[TBL] [Abstract][Full Text] [Related]
30. Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV).
Huber B; Schellenbacher C; Shafti-Keramat S; Jindra C; Christensen N; Kirnbauer R
PLoS One; 2017; 12(1):e0169533. PubMed ID: 28056100
[TBL] [Abstract][Full Text] [Related]
31. Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses.
Pouyanfard S; Spagnoli G; Bulli L; Balz K; Yang F; Odenwald C; Seitz H; Mariz FC; Bolchi A; Ottonello S; Müller M
J Virol; 2018 Feb; 92(4):. PubMed ID: 29212932
[TBL] [Abstract][Full Text] [Related]
32. Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2.
Gambhira R; Jagu S; Karanam B; Gravitt PE; Culp TD; Christensen ND; Roden RB
J Virol; 2007 Nov; 81(21):11585-92. PubMed ID: 17715230
[TBL] [Abstract][Full Text] [Related]
33. Furin Cleavage of L2 during Papillomavirus Infection: Minimal Dependence on Cyclophilins.
Bronnimann MP; Calton CM; Chiquette SF; Li S; Lu M; Chapman JA; Bratton KN; Schlegel AM; Campos SK
J Virol; 2016 Jul; 90(14):6224-6234. PubMed ID: 27122588
[TBL] [Abstract][Full Text] [Related]
34. Optimized production strategy of the major capsid protein HPV 16L1 non-assembly variant in E. coli.
Roos N; Breiner B; Preuss L; Lilie H; Hipp K; Herrmann H; Horn T; Biener R; Iftner T; Simon C
Protein Expr Purif; 2020 Nov; 175():105690. PubMed ID: 32681956
[TBL] [Abstract][Full Text] [Related]
35. APOBEC3A and 3C decrease human papillomavirus 16 pseudovirion infectivity.
Ahasan MM; Wakae K; Wang Z; Kitamura K; Liu G; Koura M; Imayasu M; Sakamoto N; Hanaoka K; Nakamura M; Kyo S; Kondo S; Fujiwara H; Yoshizaki T; Mori S; Kukimoto I; Muramatsu M
Biochem Biophys Res Commun; 2015 Feb; 457(3):295-9. PubMed ID: 25576866
[TBL] [Abstract][Full Text] [Related]
36. Amino acid sequence diversity of the major human papillomavirus capsid protein: implications for current and next generation vaccines.
Ahmed AI; Bissett SL; Beddows S
Infect Genet Evol; 2013 Aug; 18():151-9. PubMed ID: 23722024
[TBL] [Abstract][Full Text] [Related]
37. High-risk HPV L1 capsid protein as a marker of cervical intraepithelial neoplasia in high-risk HPV-positive women with minor cytological abnormalities.
Norman I; Hjerpe A; Andersson S
Oncol Rep; 2013 Aug; 30(2):695-700. PubMed ID: 23756570
[TBL] [Abstract][Full Text] [Related]
38. Virus-like Particle-Based L2 Vaccines against HPVs: Where Are We Today?
Yadav R; Zhai L; Tumban E
Viruses; 2019 Dec; 12(1):. PubMed ID: 31877975
[TBL] [Abstract][Full Text] [Related]
39. N-terminal truncations on L1 proteins of human papillomaviruses promote their soluble expression in Escherichia coli and self-assembly in vitro.
Wei M; Wang D; Li Z; Song S; Kong X; Mo X; Yang Y; He M; Li Z; Huang B; Lin Z; Pan H; Zheng Q; Yu H; Gu Y; Zhang J; Li S; Xia N
Emerg Microbes Infect; 2018 Sep; 7(1):160. PubMed ID: 30254257
[TBL] [Abstract][Full Text] [Related]
40. A Novel PDZ Domain Interaction Mediates the Binding between Human Papillomavirus 16 L2 and Sorting Nexin 27 and Modulates Virion Trafficking.
Pim D; Broniarczyk J; Bergant M; Playford MP; Banks L
J Virol; 2015 Oct; 89(20):10145-55. PubMed ID: 26202251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
